ILLUMINATE

Trials for Primary Hyperoxaluria Type 1 (PH1)

A Family of Clinical Trials for Primary Hyperoxaluria Type 1 (PH1)

Find out if you or someone you know may be eligible for the ILLUMINATE PH1 clinical trials.
See if you may qualify

For people with Primary Hyperoxaluria Type 1 (PH1), treatment options are limited. The ILLUMINATE clinical research trials are studying the safety and effectiveness of an investigational medication for people with PH1.

About the ILLUMINATE PH1 Clinical Trials

The ILLUMINATE clinical research studies are for both children and adults with PH1. Learn more about the trials, and find out if ILLUMINATE might be an option for you or someone you care for.

About PH1

Primary Hyperoxaluria Type 1 is a rare, inherited condition that can result in painful, recurrent kidney stones and may eventually lead to kidney failure. Learn more about how the ILLUMINATE studies are working to research an investigational medicine for children and adults with PH1.

About Lumasiran (ALN-GO1)

Lumasiran is an investigational medication being studied for its safety and effectiveness in the treatment of PH1. Researchers at Alnylam Pharmaceuticals are using RNA Interference (RNAi) technology to research and develop medicines for PH1 and other rare, inherited conditions.

Understanding Clinical Research and Clinical Trials

Clinical research can be intimidating, but it doesn’t have to be. This page has information and a glossary of clinical research terms help you navigate the often confusing world of clinical trials.